CharlestonPharma,LLC

company

About

CharlestonPharma is focused on developing innovative therapeutic antibodies and related diagnostic tests for cancer patients.

  • 1 - 10

Details

Last Funding Type
Seed
Last Funding Money Raised
$1.60M
Industries
Biotechnology,Health Diagnostics,Medical,Therapeutics
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

CharlestonPharma is focused on developing innovative therapeutic antibodies and related diagnostic tests for cancer patients and healthcare providers.

Laboratory studies provide compelling evidence that inhibition of the cell surface target, nucleolin, selectively kills a variety of cancer cells without dose-limiting toxicity to the normal cells of the body. With an exclusive worldwide license from the Medical University of South Carolina (MUSC) for eight specific antibodies as well as the process to make additional fully-human antibodies to this target and worldwide exclusive licenses to the method of treating cancer with an anti-nucleolin antibody and the method for for the diagnosis and prognosis of malignant disease which includes the detection of nucleolin in the cell surface of a patient’s tumor cells tissue biopsy, they are focused on demonstrating preclinical proof of concept for their anti-nucleolin monoclonal antibodies. Research in their laboratories at the Charleston Innovation Center is designed to identify the most promising antibodies for subsequent in vivo studies that will establish preclinical efficacy and safety.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.60M
CharlestonPharma,LLC has raised a total of $1.60M in funding over 2 rounds. Their latest funding was raised on Jan 29, 2013 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 29, 2013 Seed $1.60M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
CharlestonPharma,LLC is funded by 1 investors. Sears Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
Sears Capital Management Seed